CompletedPhase 2NCT04947124
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Studying Sturge-Weber syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Qlaris Bio, Inc.
- Principal Investigator
- B. Wirostko, M.D.Qlaris Bio, Inc.
- Intervention
- QLS-101ophthalmic solution 1%(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2022
Study locations (1)
- Duke Eye Center, Durham, North Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04947124 on ClinicalTrials.govOther trials for Sturge-Weber syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT04717427Longitudinal Studies to Identify Biomarkers for Sturge-Weber SyndromeUniversity of Illinois at Chicago
- ACTIVE NOT RECRUITINGNANCT04517565Longitudinal Neuroimaging in Sturge-Weber SyndromeWayne State University
- ACTIVE NOT RECRUITINGNCT01425944Innovative Approaches to Gauge Progression of Sturge-Weber SyndromeHugo W. Moser Research Institute at Kennedy Krieger, Inc.